(VIANEWS) – The Market ended the session with BERGENBIO (BGBIO.OL) jumping 16.73% to kr10.59 on Friday while Oslo Børs Benchmark Index_GI fell 0.25% to kr1,407.43.
BERGENBIO’s last close was kr9.07, 30.39% under its 52-week high of kr13.03.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-15.16.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BERGENBIO’s EBITDA is -2.91.
Volatility
BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.03%, a negative 1.17%, and a positive 2.94%.
BERGENBIO’s highest amplitude of average volatility was 2.38% (last week), 2.77% (last month), and 2.94% (last quarter).
Moving Average
BERGENBIO’s value is way higher than its 50-day moving average of kr0.13 and way above its 200-day moving average of kr4.18.
Yearly Top and Bottom Value
BERGENBIO’s stock is valued at kr10.59 at 22:31 EST, way under its 52-week high of kr13.03 and way above its 52-week low of kr0.08.
More news about BERGENBIO (BGBIO.OL).
